# Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes

> **NCT00191633** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 200 (—)

## Conditions studied

- Attention-Deficit/Hyperactivity Disorder

## Interventions

- **DRUG:** Atomoxetine

## Key facts

- **NCT ID:** NCT00191633
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** —
- **Final completion:** 2006-06
- **Target enrollment:** 200 (—)
- **Last updated:** 2007-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191633, "Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT00191633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*